Literature DB >> 17034994

Stem cell based therapies to treat muscular dystrophy.

F D Price1, K Kuroda, M A Rudnicki.   

Abstract

Muscular dystrophies comprise a heterogeneous group of neuromuscular disorders, characterized by progressive muscle wasting, for which no satisfactory treatment exists. Multiple stem cell populations, both of adult or embryonic origin, display myogenic potential and have been assayed for their ability to correct the dystrophic phenotype. To date, many of these described methods have failed, underlying the need to identify the mechanisms controlling myogenic potential, homing of donor populations to the musculature, and avoidance of the immune response. Recent results focus on the fresh isolation of satellite cells and the use of multiple growth factors to promote mesangioblast migration, both of which promote muscle regeneration. Throughout this chapter, various stem cell based therapies will be introduced and evaluated based on their potential to treat muscular dystrophy in an effective and efficient manner.

Entities:  

Mesh:

Year:  2006        PMID: 17034994     DOI: 10.1016/j.bbadis.2006.08.011

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  34 in total

1.  MASTR directs MyoD-dependent satellite cell differentiation during skeletal muscle regeneration.

Authors:  Mayssa H Mokalled; Aaron N Johnson; Esther E Creemers; Eric N Olson
Journal:  Genes Dev       Date:  2012-01-15       Impact factor: 11.361

2.  Photoacoustic imaging of mesenchymal stem cells in living mice via silica-coated gold nanorods.

Authors:  Jesse V Jokerst; Mridhula Thangaraj; Paul J Kempen; Robert Sinclair; Sanjiv S Gambhir
Journal:  ACS Nano       Date:  2012-06-20       Impact factor: 15.881

3.  Use of Encapsulated Stem Cells to Overcome the Bottleneck of Cell Availability for Cell Therapy Approaches.

Authors:  D Freimark; P Pino-Grace; S Pohl; C Weber; C Wallrapp; P Geigle; R Pörtner; P Czermak
Journal:  Transfus Med Hemother       Date:  2010-03-08       Impact factor: 3.747

4.  Bone marrow side population cells are enriched for progenitors capable of myogenic differentiation.

Authors:  Eric S Luth; Susan J Jun; McKenzie K Wessen; Kalliopi Liadaki; Emanuela Gussoni; Louis M Kunkel
Journal:  J Cell Sci       Date:  2008-04-08       Impact factor: 5.285

5.  Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer.

Authors:  Bo Wu; Hong M Moulton; Patrick L Iversen; Jiangang Jiang; Juan Li; Jianbin Li; Christopher F Spurney; Arpana Sali; Alfredo D Guerron; Kanneboyina Nagaraju; Timothy Doran; Peijuan Lu; Xiao Xiao; Qi Long Lu
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-19       Impact factor: 11.205

Review 6.  Duchenne muscular dystrophy: current cell therapies.

Authors:  Dorota Sienkiewicz; Wojciech Kulak; Bożena Okurowska-Zawada; Grażyna Paszko-Patej; Katarzyna Kawnik
Journal:  Ther Adv Neurol Disord       Date:  2015-07       Impact factor: 6.570

Review 7.  CD117(+) amniotic fluid stem cells: state of the art and future perspectives.

Authors:  Mara Cananzi; Paolo De Coppi
Journal:  Organogenesis       Date:  2012-07-01       Impact factor: 2.500

Review 8.  Repairing skeletal muscle: regenerative potential of skeletal muscle stem cells.

Authors:  Francesco Saverio Tedesco; Arianna Dellavalle; Jordi Diaz-Manera; Graziella Messina; Giulio Cossu
Journal:  J Clin Invest       Date:  2010-01       Impact factor: 14.808

Review 9.  Mesenchymal stem cells: emerging therapy for Duchenne muscular dystrophy.

Authors:  Chad D Markert; Anthony Atala; Jennifer K Cann; George Christ; Mark Furth; Fabrisia Ambrosio; Martin K Childers
Journal:  PM R       Date:  2009-06       Impact factor: 2.298

Review 10.  Redox regulation of autophagy in skeletal muscle.

Authors:  George G Rodney; Rituraj Pal; Reem Abo-Zahrah
Journal:  Free Radic Biol Med       Date:  2016-05-14       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.